Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.
Rodon J, Soria JC, Berger R, Miller WH, Rubin E, Kugel A, Tsimberidou A, Saintigny P, Ackerstein A, Braña I, Loriot Y, Afshar M, Miller V, Wunder F, Bresson C, Martini JF, Raynaud J, Mendelsohn J, Batist G, Onn A, Tabernero J, Schilsky RL, Lazar V, Lee JJ, Kurzrock R.
Rodon J, et al.
Nat Med. 2019 May;25(5):751-758. doi: 10.1038/s41591-019-0424-4. Epub 2019 Apr 22.
Nat Med. 2019.
PMID: 31011205
Free PMC article.
Clinical Trial.
The most common diagnoses were colon, head and neck, and lung cancers. Among the 107 patients, the rate of stable disease 6 months and partial or complete response was 26.2% (arm A: 23.2%; arm B: 31.6% (P = 0.37)). ...
The most common diagnoses were colon, head and neck, and lung cancers. Among the 107 patients, the rate of stable disease 6 months an …